

Transmitted herewith is a copy of the "Sequence Listing" (sheets 1/16 through 16/16) in paper form for the above-identified patent application as required by 37 C.F.R. §1.821(c) and a copy of the "Sequence Listing" in computer readable form as required by 37 C.F.R. §1.821(e). As required by 37 C.F.R. §1.821(f), Applicant's Attorney hereby states that the content of the "Sequence Listing" in paper form and the computer readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

Applicant's Attorney submits the following amendments to comply with 37 C.F.R. §1.825:

In the Specification

Please insert the attached "Sequence Listing" (sheets 1/16 through 16/16), and comprising SEQ ID NOS: 1-25, into the above-referenced application.

Please replace the paragraph at page 4, line 23 through page 5, line 2 with the following paragraph:

AI  
Figure 5A is the P1 peptide amino acid sequence (SEQ ID NO: 25). When liberated from P1, SIYRYYGL (SEQ ID NO: 1) (**boldface**) binds to K<sup>b</sup> to form the peptide-MHC complex recognized by the 2C TCR. In P1, SIYRYYGL (SEQ ID NO: 1) is flanked 5' and 3' by sequences that lie immediately upstream and downstream, respectively, of peptide bonds that are cleaved (see arrows) in murine cells to liberate naturally occurring peptides (SIINFEKL (SEQ ID NO: 2) from ovalbumin (Ova) and LSPFPFDL (SEQ ID NO: 3) from  $\alpha$ -ketoglutaraldehyde dehydrogenase ( $\alpha$ KG) (Falk, K., *et al.*, *Eur. J. Immunol.*, 22:1323-1326 (1992); Ukada, K., *et al.*, *J. Immunol.*, 157:670-678 (1996)).

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (page i).

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Anne J. Collins

Anne J. Collins

Registration No.: 40,564

Telephone (781) 861-6240

Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799

Date:

*September 27, 2001*